Lyra Therapeutics is a clinical-stage company developing medicines precisely designed to target ear, nose and throat (ENT) diseases.
Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients.
Building on expertise in materials science, drug development and formulation, the Lyra team has developed a proprietary platform that is designed to enable long-acting, local delivery of medications over an extended period of time, directly targeting tissue deep in the nasal passages. Based on clinical results, this new therapeutic approach has the potential to provide significantly improved patient outcomes beyond the limited treatment and surgical options currently available for ENT diseases.
Headquartered in the Boston area, Lyra Therapeutics was founded by academic luminaries in the fields of chemistry, materials science and biotechnology, and is backed by leading life science investors.